|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Full details on the surprise success of a Novartis anti-inflammatory drug in cutting cardiovascular risk for heart attack survivors will be presented at a medical meeting on Aug. 27, conference organisers said on Thursday. The so-called CANTOS study will be one of the highlights of the annual meeting of the European Society of Cardiology (ESC), the region's largest professional gathering of heart specialists. Novartis said last week that canakinumab had been found to reduce further heart attacks or strokes in a large study, confounding expectations among analysts who had not expected it to work, given past setbacks with anti-inflammatory approaches.
The Petya ransomware is a virus that is spreading across the world and is now on computers in 65 countries. The spread of the Petya ransomware has seen it hitting several different companies and we have a list of them. You can follow these links to learn more about the companies affected by the Petya ransomware.